MTOR and neoplasm: The feedback activation of STAT3 by PI3K/mTOR inhibitors raises the possibility that simultaneously targeting PI3K/mTOR and STAT3 activity in PTEN-deficient cancer cells can synergistically inhibit tumor progression.